These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. RTS,S Clinical Trials Partnership Lancet; 2015 Jul; 386(9988):31-45. PubMed ID: 25913272 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. RTS,S Clinical Trials Partnership PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396 [TBL] [Abstract][Full Text] [Related]
8. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331 [TBL] [Abstract][Full Text] [Related]
9. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786 [TBL] [Abstract][Full Text] [Related]
10. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR; Malar J; 2011 Aug; 10():224. PubMed ID: 21816029 [TBL] [Abstract][Full Text] [Related]
11. Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi. Witte D; Cunliffe NA; Turner AM; Ngulube E; Ofori-Anyinam O; Vekemans J; Chimpeni P; Lievens M; Wilson TP; Njiram'madzi J; Mendoza YG; Leach A Pediatr Infect Dis J; 2018 May; 37(5):483-491. PubMed ID: 29432383 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial. Otieno L; Oneko M; Otieno W; Abuodha J; Owino E; Odero C; Mendoza YG; Andagalu B; Awino N; Ivinson K; Heerwegh D; Otsyula N; Oziemkowska M; Usuf EA; Otieno A; Otieno K; Leboulleux D; Leach A; Oyieko J; Slutsker L; Lievens M; Cowden J; Lapierre D; Kariuki S; Ogutu B; Vekemans J; Hamel MJ Lancet Infect Dis; 2016 Oct; 16(10):1134-1144. PubMed ID: 27394191 [TBL] [Abstract][Full Text] [Related]
13. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. Olotu A; Fegan G; Wambua J; Nyangweso G; Leach A; Lievens M; Kaslow DC; Njuguna P; Marsh K; Bejon P N Engl J Med; 2016 Jun; 374(26):2519-29. PubMed ID: 27355532 [TBL] [Abstract][Full Text] [Related]
14. The Advanced Development Pathway of the RTS,S/AS01 Vaccine. von Seidlein L Methods Mol Biol; 2019; 2013():177-187. PubMed ID: 31267502 [TBL] [Abstract][Full Text] [Related]
15. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768 [TBL] [Abstract][Full Text] [Related]
16. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials. Agnandji ST; Fernandes JF; Bache EB; Ramharter M Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872 [TBL] [Abstract][Full Text] [Related]
17. Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi. Bell GJ; Loop M; Topazian HM; Hudgens M; Mvalo T; Juliano JJ; Kamthunzi P; Tegha G; Mofolo I; Hoffman I; Bailey JA; Emch M Vaccine; 2020 May; 38(25):4079-4087. PubMed ID: 32362527 [TBL] [Abstract][Full Text] [Related]
18. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique. Campo JJ; Sacarlal J; Aponte JJ; Aide P; Nhabomba AJ; Dobaño C; Alonso PL Vaccine; 2014 Apr; 32(19):2209-16. PubMed ID: 24631081 [TBL] [Abstract][Full Text] [Related]